# SGPL1

## Overview
SGPL1 is a gene that encodes the enzyme sphingosine-1-phosphate lyase 1, which is a crucial component of the sphingolipid metabolic pathway. This enzyme is responsible for the irreversible degradation of sphingosine-1-phosphate (S1P), a bioactive lipid that plays a significant role in various cellular processes, including immune cell trafficking, angiogenesis, and cell transformation (Saba2019Fifty; Maharaj2020Sphingosine1phosphate). As a pyridoxal 5'-phosphate (PLP)-dependent enzyme, sphingosine-1-phosphate lyase 1 functions as a homodimer and is predominantly localized in the endoplasmic reticulum (Saba2019Fifty). The enzyme's activity is essential for maintaining sphingolipid homeostasis and preventing the accumulation of toxic intermediates, thereby ensuring proper cellular function (Bektas2010Sphingosine). Mutations in SGPL1 can lead to a spectrum of clinical conditions, collectively known as sphingosine phosphate lyase insufficiency syndrome (SPLIS), which includes nephrotic syndrome, adrenal insufficiency, and neurological defects (Saba2021GenotypePhenotype; Atreya2022Neurological).

## Function
SGPL1 encodes sphingosine-1-phosphate lyase, an enzyme crucial for the irreversible degradation of sphingosine-1-phosphate (S1P), a bioactive lipid involved in various cellular processes. This enzyme catalyzes the final step in the sphingolipid metabolic pathway, converting S1P into phosphoethanolamine and hexadecanal, thus regulating the exit point of sphingolipid metabolism (Saba2019Fifty; Maharaj2020Sphingosine1phosphate). SGPL1 is a pyridoxal 5'-phosphate (PLP)-dependent enzyme that functions as a homodimer and is enriched in the endoplasmic reticulum (Saba2019Fifty).

In healthy human cells, SGPL1 plays a vital role in maintaining sphingolipid homeostasis, preventing the accumulation of toxic intermediates, and ensuring proper cellular functions related to sphingolipid metabolism (Saba2019Fifty). It is involved in immune cell trafficking, angiogenesis, and cell transformation by regulating S1P levels, which act as ligands for G-protein coupled receptors involved in these processes (Maharaj2020Sphingosine1phosphate). SGPL1 also influences mitochondrial function and steroidogenesis, with its deficiency leading to mitochondrial dysfunction and altered steroid production (Maharaj2020Sphingosine1phosphate). The enzyme's activity is essential for maintaining lipid balance, impacting broader lipid metabolic pathways and cellular energy metabolism (Bektas2010Sphingosine).

## Clinical Significance
Mutations in the SGPL1 gene, which encodes sphingosine-1-phosphate lyase, are linked to a range of clinical conditions collectively known as sphingosine phosphate lyase insufficiency syndrome (SPLIS). This syndrome is characterized by steroid-resistant nephrotic syndrome, primary adrenal insufficiency, and various neurological defects, including sensorineural hearing loss, cranial nerve defects, and neurodegeneration (Saba2021GenotypePhenotype; Atreya2022Neurological). The nephrotic syndrome often presents with focal segmental glomerulosclerosis (FSGS) and is resistant to steroid treatment, sometimes necessitating kidney transplants (Prasad2017Sphingosine1phosphate). 

SGPL1 mutations also lead to skin conditions such as ichthyosis and acanthosis, hypothyroidism, and lymphopenia due to disrupted lymphocyte egress from lymphoid tissues (Saba2021GenotypePhenotype; Lovric2017Mutations). The accumulation of sphingolipid intermediates, such as sphingosine-1-phosphate (S1P), due to SGPL1 deficiency, is thought to contribute to these pathologies by disrupting normal cellular functions and signaling pathways (Lovric2017Mutations; Prasad2017Sphingosine1phosphate). 

Altered SGPL1 expression is also associated with cancer progression and immune system dysfunction, highlighting its broader clinical significance (Lovric2017Mutations). Gene therapy and vitamin B6 supplementation are being explored as potential treatments for SPLIS, with gene therapy showing promise in preclinical models (Saba2021GenotypePhenotype).

## Interactions
SGPL1, or sphingosine-1-phosphate lyase 1, is involved in several protein interactions that influence cellular processes. The enzyme is primarily localized in the endoplasmic reticulum, where it interacts with proteins involved in lipid metabolism and signaling pathways. These interactions are crucial for the regulation of cell growth, survival, and migration (Lovric2017Mutations).

Mutations in SGPL1 can disrupt its normal interactions, leading to altered protein localization and the formation of abnormal cytoplasmic aggregates. This mislocalization affects the enzyme's ability to participate in its usual protein interactions, contributing to disease phenotypes such as nephrotic syndrome and adrenal insufficiency (Lovric2017Mutations).

SGPL1 also plays a role in the DNA damage response and apoptosis. It interacts with pathways involving p53 and caspase 2, promoting apoptosis when overexpressed. This interaction highlights its involvement in cellular stress responses and its potential impact on cell fate decisions (Lovric2017Mutations).

In the context of mitochondrial function, SGPL1 deficiency has been linked to changes in mitochondrial dynamics and function, suggesting interactions with proteins involved in mitochondrial morphology and the electron transport chain (Maharaj2020Sphingosine1phosphate). These interactions are critical for maintaining cellular energy balance and preventing apoptosis.


## References


[1. (Maharaj2020Sphingosine1phosphate) A. Maharaj, J. Williams, T. Bradshaw, T. Güran, D. Braslavsky, J. Casas, L.F. Chan, L.A. Metherell, and R. Prasad. Sphingosine-1-phosphate lyase (sgpl1) deficiency is associated with mitochondrial dysfunction. The Journal of Steroid Biochemistry and Molecular Biology, 202:105730, September 2020. URL: http://dx.doi.org/10.1016/j.jsbmb.2020.105730, doi:10.1016/j.jsbmb.2020.105730. This article has 19 citations.](https://doi.org/10.1016/j.jsbmb.2020.105730)

[2. (Saba2019Fifty) Julie D. Saba. Fifty years of lyase and a moment of truth: sphingosine phosphate lyase from discovery to disease. Journal of Lipid Research, 60(3):456–463, March 2019. URL: http://dx.doi.org/10.1194/jlr.s091181, doi:10.1194/jlr.s091181. This article has 61 citations and is from a peer-reviewed journal.](https://doi.org/10.1194/jlr.s091181)

[3. (Bektas2010Sphingosine) Meryem Bektas, Maria Laura Allende, Bridgin G. Lee, WeiPing Chen, Marcelo J. Amar, Alan T. Remaley, Julie D. Saba, and Richard L. Proia. Sphingosine 1-phosphate lyase deficiency disrupts lipid homeostasis in liver. Journal of Biological Chemistry, 285(14):10880–10889, April 2010. URL: http://dx.doi.org/10.1074/jbc.m109.081489, doi:10.1074/jbc.m109.081489. This article has 165 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m109.081489)

[4. (Saba2021GenotypePhenotype) Julie D. Saba, Nancy Keller, Jen-Yeu Wang, Felicia Tang, Avi Slavin, and Yizhuo Shen. Genotype/phenotype interactions and first steps toward targeted therapy for sphingosine phosphate lyase insufficiency syndrome. Cell Biochemistry and Biophysics, 79(3):547–559, June 2021. URL: http://dx.doi.org/10.1007/s12013-021-01013-9, doi:10.1007/s12013-021-01013-9. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s12013-021-01013-9)

[5. (Atreya2022Neurological) Krishan B. Atreya and Julie D. Saba. Neurological consequences of sphingosine phosphate lyase insufficiency. Frontiers in Cellular Neuroscience, September 2022. URL: http://dx.doi.org/10.3389/fncel.2022.938693, doi:10.3389/fncel.2022.938693. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fncel.2022.938693)

[6. (Lovric2017Mutations) Svjetlana Lovric, Sara Goncalves, Heon Yung Gee, Babak Oskouian, Honnappa Srinivas, Won-Il Choi, Shirlee Shril, Shazia Ashraf, Weizhen Tan, Jia Rao, Merlin Airik, David Schapiro, Daniela A. Braun, Carolin E. Sadowski, Eugen Widmeier, Tilman Jobst-Schwan, Johanna Magdalena Schmidt, Vladimir Girik, Guido Capitani, Jung H. Suh, Noëlle Lachaussée, Christelle Arrondel, Julie Patat, Olivier Gribouval, Monica Furlano, Olivia Boyer, Alain Schmitt, Vincent Vuiblet, Seema Hashmi, Rainer Wilcken, Francois P. Bernier, A. Micheil Innes, Jillian S. Parboosingh, Ryan E. Lamont, Julian P. Midgley, Nicola Wright, Jacek Majewski, Martin Zenker, Franz Schaefer, Navina Kuss, Johann Greil, Thomas Giese, Klaus Schwarz, Vilain Catheline, Denny Schanze, Ingolf Franke, Yves Sznajer, Anne S. Truant, Brigitte Adams, Julie Désir, Ronald Biemann, York Pei, Elisabet Ars, Nuria Lloberas, Alvaro Madrid, Vikas R. Dharnidharka, Anne M. Connolly, Marcia C. Willing, Megan A. Cooper, Richard P. Lifton, Matias Simons, Howard Riezman, Corinne Antignac, Julie D. Saba, and Friedhelm Hildebrandt. Mutations in sphingosine-1-phosphate lyase cause nephrosis with ichthyosis and adrenal insufficiency. Journal of Clinical Investigation, 127(3):912–928, February 2017. URL: http://dx.doi.org/10.1172/jci89626, doi:10.1172/jci89626. This article has 159 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci89626)

[7. (Prasad2017Sphingosine1phosphate) Rathi Prasad, Irene Hadjidemetriou, Avinaash Maharaj, Eirini Meimaridou, Federica Buonocore, Moin Saleem, Jenny Hurcombe, Agnieszka Bierzynska, Eliana Barbagelata, Ignacio Bergadá, Hamilton Cassinelli, Urmi Das, Ruth Krone, Bulent Hacihamdioglu, Erkan Sari, Ediz Yesilkaya, Helen L. Storr, Maria Clemente, Monica Fernandez-Cancio, Nuria Camats, Nanik Ram, John C. Achermann, Paul P. Van Veldhoven, Leonardo Guasti, Debora Braslavsky, Tulay Guran, and Louise A. Metherell. Sphingosine-1-phosphate lyase mutations cause primary adrenal insufficiency and steroid-resistant nephrotic syndrome. Journal of Clinical Investigation, 127(3):942–953, February 2017. URL: http://dx.doi.org/10.1172/jci90171, doi:10.1172/jci90171. This article has 135 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci90171)